Study Protocol for the DETECTIVE Study

An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer

Thomas B L Lam, Steven MacLennan, Karin Plass, Peter-Paul M Willemse, Malcolm D Mason, Philip Cornford, James Donaldson, Niall F Davis, Paolo Dell'Oglio, Christian Fankhauser, Nikos Grivas, Alexandre Ingels, Michael Lardas, Matthew Liew, Karl H Pang, Catherine Paterson, Muhammad I Omar, Fabio Zattoni, Karel T Buddingh, Thomas Van den Broeck & 20 others Marcus G Cumberbatch, Nicola Fossati, Tobias Gross, Lisa Moris, Ivo G Schoots, Roderick C N van den Bergh, Erik Briers, Stefano Fanti, Maria De Santis, Silke Gillessen, Jeremy P Grummet, Ann M Henry, Henk G van der Poel, Theodorus H van der Kwast, Olivier Rouvière, Derya Tilki, Thomas Wiegel, James N'Dow, Hendrik Van Poppel, Nicolas Mottet

Research output: Contribution to journalLetter

3 Citations (Scopus)

Abstract

Deferred active treatment (DAT) strategies for men with localised prostate cancer have emerged as a viable alternative to radical intervention as we aim to avoid the consequences of overtreatment. Nevertheless, such strategies remain controversial, with significant uncertainty and heterogeneity in all domains, including criteria for patient selection, the nature and timing of interventions during follow-up, criteria and thresholds for reclassification, and which outcome measures should be prioritised [1], [2], [3]. These are important barriers to the conduct and uptake of DAT by clinicians and patients as they prohibit comparison of the clinical effectiveness of different protocols. In order to address these issues in a comprehensive, robust, and systematic manner, the European Association of Urology (EAU) Prostate Cancer Guidelines Panel, in partnership with other leading guideline authorities and organisations (listed in Appendix A), has commissioned a project to develop consensus statements for all domains relating to DAT to standardise clinical practice and research.
Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalEuropean Urology
DOIs
Publication statusE-pub ahead of print - 22 Nov 2018
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Guidelines
Patient Selection
Uncertainty
Therapeutics
Outcome Assessment (Health Care)
Research
Medical Overuse
Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate

Cite this

Lam, Thomas B L ; MacLennan, Steven ; Plass, Karin ; Willemse, Peter-Paul M ; Mason, Malcolm D ; Cornford, Philip ; Donaldson, James ; Davis, Niall F ; Dell'Oglio, Paolo ; Fankhauser, Christian ; Grivas, Nikos ; Ingels, Alexandre ; Lardas, Michael ; Liew, Matthew ; Pang, Karl H ; Paterson, Catherine ; Omar, Muhammad I ; Zattoni, Fabio ; Buddingh, Karel T ; Van den Broeck, Thomas ; Cumberbatch, Marcus G ; Fossati, Nicola ; Gross, Tobias ; Moris, Lisa ; Schoots, Ivo G ; van den Bergh, Roderick C N ; Briers, Erik ; Fanti, Stefano ; De Santis, Maria ; Gillessen, Silke ; Grummet, Jeremy P ; Henry, Ann M ; van der Poel, Henk G ; van der Kwast, Theodorus H ; Rouvière, Olivier ; Tilki, Derya ; Wiegel, Thomas ; N'Dow, James ; Van Poppel, Hendrik ; Mottet, Nicolas. / Study Protocol for the DETECTIVE Study : An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. In: European Urology. 2018 ; pp. 1-4.
@article{1af3d505bcd048829de0e7955899388d,
title = "Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer",
abstract = "Deferred active treatment (DAT) strategies for men with localised prostate cancer have emerged as a viable alternative to radical intervention as we aim to avoid the consequences of overtreatment. Nevertheless, such strategies remain controversial, with significant uncertainty and heterogeneity in all domains, including criteria for patient selection, the nature and timing of interventions during follow-up, criteria and thresholds for reclassification, and which outcome measures should be prioritised [1], [2], [3]. These are important barriers to the conduct and uptake of DAT by clinicians and patients as they prohibit comparison of the clinical effectiveness of different protocols. In order to address these issues in a comprehensive, robust, and systematic manner, the European Association of Urology (EAU) Prostate Cancer Guidelines Panel, in partnership with other leading guideline authorities and organisations (listed in Appendix A), has commissioned a project to develop consensus statements for all domains relating to DAT to standardise clinical practice and research.",
author = "Lam, {Thomas B L} and Steven MacLennan and Karin Plass and Willemse, {Peter-Paul M} and Mason, {Malcolm D} and Philip Cornford and James Donaldson and Davis, {Niall F} and Paolo Dell'Oglio and Christian Fankhauser and Nikos Grivas and Alexandre Ingels and Michael Lardas and Matthew Liew and Pang, {Karl H} and Catherine Paterson and Omar, {Muhammad I} and Fabio Zattoni and Buddingh, {Karel T} and {Van den Broeck}, Thomas and Cumberbatch, {Marcus G} and Nicola Fossati and Tobias Gross and Lisa Moris and Schoots, {Ivo G} and {van den Bergh}, {Roderick C N} and Erik Briers and Stefano Fanti and {De Santis}, Maria and Silke Gillessen and Grummet, {Jeremy P} and Henry, {Ann M} and {van der Poel}, {Henk G} and {van der Kwast}, {Theodorus H} and Olivier Rouvi{\`e}re and Derya Tilki and Thomas Wiegel and James N'Dow and {Van Poppel}, Hendrik and Nicolas Mottet",
year = "2018",
month = "11",
day = "22",
doi = "10.1016/j.eururo.2018.11.009",
language = "English",
pages = "1--4",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",

}

Lam, TBL, MacLennan, S, Plass, K, Willemse, P-PM, Mason, MD, Cornford, P, Donaldson, J, Davis, NF, Dell'Oglio, P, Fankhauser, C, Grivas, N, Ingels, A, Lardas, M, Liew, M, Pang, KH, Paterson, C, Omar, MI, Zattoni, F, Buddingh, KT, Van den Broeck, T, Cumberbatch, MG, Fossati, N, Gross, T, Moris, L, Schoots, IG, van den Bergh, RCN, Briers, E, Fanti, S, De Santis, M, Gillessen, S, Grummet, JP, Henry, AM, van der Poel, HG, van der Kwast, TH, Rouvière, O, Tilki, D, Wiegel, T, N'Dow, J, Van Poppel, H & Mottet, N 2018, 'Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer', European Urology, pp. 1-4. https://doi.org/10.1016/j.eururo.2018.11.009

Study Protocol for the DETECTIVE Study : An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. / Lam, Thomas B L; MacLennan, Steven; Plass, Karin; Willemse, Peter-Paul M; Mason, Malcolm D; Cornford, Philip; Donaldson, James; Davis, Niall F; Dell'Oglio, Paolo; Fankhauser, Christian; Grivas, Nikos; Ingels, Alexandre; Lardas, Michael; Liew, Matthew; Pang, Karl H; Paterson, Catherine; Omar, Muhammad I; Zattoni, Fabio; Buddingh, Karel T; Van den Broeck, Thomas; Cumberbatch, Marcus G; Fossati, Nicola; Gross, Tobias; Moris, Lisa; Schoots, Ivo G; van den Bergh, Roderick C N; Briers, Erik; Fanti, Stefano; De Santis, Maria; Gillessen, Silke; Grummet, Jeremy P; Henry, Ann M; van der Poel, Henk G; van der Kwast, Theodorus H; Rouvière, Olivier; Tilki, Derya; Wiegel, Thomas; N'Dow, James; Van Poppel, Hendrik; Mottet, Nicolas.

In: European Urology, 22.11.2018, p. 1-4.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Study Protocol for the DETECTIVE Study

T2 - An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer

AU - Lam, Thomas B L

AU - MacLennan, Steven

AU - Plass, Karin

AU - Willemse, Peter-Paul M

AU - Mason, Malcolm D

AU - Cornford, Philip

AU - Donaldson, James

AU - Davis, Niall F

AU - Dell'Oglio, Paolo

AU - Fankhauser, Christian

AU - Grivas, Nikos

AU - Ingels, Alexandre

AU - Lardas, Michael

AU - Liew, Matthew

AU - Pang, Karl H

AU - Paterson, Catherine

AU - Omar, Muhammad I

AU - Zattoni, Fabio

AU - Buddingh, Karel T

AU - Van den Broeck, Thomas

AU - Cumberbatch, Marcus G

AU - Fossati, Nicola

AU - Gross, Tobias

AU - Moris, Lisa

AU - Schoots, Ivo G

AU - van den Bergh, Roderick C N

AU - Briers, Erik

AU - Fanti, Stefano

AU - De Santis, Maria

AU - Gillessen, Silke

AU - Grummet, Jeremy P

AU - Henry, Ann M

AU - van der Poel, Henk G

AU - van der Kwast, Theodorus H

AU - Rouvière, Olivier

AU - Tilki, Derya

AU - Wiegel, Thomas

AU - N'Dow, James

AU - Van Poppel, Hendrik

AU - Mottet, Nicolas

PY - 2018/11/22

Y1 - 2018/11/22

N2 - Deferred active treatment (DAT) strategies for men with localised prostate cancer have emerged as a viable alternative to radical intervention as we aim to avoid the consequences of overtreatment. Nevertheless, such strategies remain controversial, with significant uncertainty and heterogeneity in all domains, including criteria for patient selection, the nature and timing of interventions during follow-up, criteria and thresholds for reclassification, and which outcome measures should be prioritised [1], [2], [3]. These are important barriers to the conduct and uptake of DAT by clinicians and patients as they prohibit comparison of the clinical effectiveness of different protocols. In order to address these issues in a comprehensive, robust, and systematic manner, the European Association of Urology (EAU) Prostate Cancer Guidelines Panel, in partnership with other leading guideline authorities and organisations (listed in Appendix A), has commissioned a project to develop consensus statements for all domains relating to DAT to standardise clinical practice and research.

AB - Deferred active treatment (DAT) strategies for men with localised prostate cancer have emerged as a viable alternative to radical intervention as we aim to avoid the consequences of overtreatment. Nevertheless, such strategies remain controversial, with significant uncertainty and heterogeneity in all domains, including criteria for patient selection, the nature and timing of interventions during follow-up, criteria and thresholds for reclassification, and which outcome measures should be prioritised [1], [2], [3]. These are important barriers to the conduct and uptake of DAT by clinicians and patients as they prohibit comparison of the clinical effectiveness of different protocols. In order to address these issues in a comprehensive, robust, and systematic manner, the European Association of Urology (EAU) Prostate Cancer Guidelines Panel, in partnership with other leading guideline authorities and organisations (listed in Appendix A), has commissioned a project to develop consensus statements for all domains relating to DAT to standardise clinical practice and research.

U2 - 10.1016/j.eururo.2018.11.009

DO - 10.1016/j.eururo.2018.11.009

M3 - Letter

SP - 1

EP - 4

JO - European Urology

JF - European Urology

SN - 0302-2838

ER -